Hepatitis C Infection Clinical Trial
Official title:
Efficacy and Safety in Clinical Practice of Ombitasvir/Paritaprevir/ Ritonavir and Dasabuvir Administered for 8 Weeks (3D8) in Treatment-naïve Genotype 1b Hepatitis C Virus Infected Patients: Analysis of Data From Hepa-C Registry.
The aim of the study is to evaluate in clinical practice the efficacy and safety of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b hepatitis C virus (HCV).
HCV chronic infection affects 200 million people worldwide. HCV antiviral treatment has evolved rapidly since 2011. The introduction of direct-acting antivirals (DAAs) achieve great effectiveness with minimum SAEs and short treatment duration. However, studies evaluating efficacy and safety of ombitasvir/paritaprevir/ ritonavir and dasabuvir during 8 weeks are limited in real clinical practice. The aim of the study is to evaluate in clinical practice the efficacy and safety of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b hepatitis C virus (HCV). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01771653 -
Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection
|
N/A | |
| Recruiting |
NCT03601546 -
Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam
|
||
| Completed |
NCT02362217 -
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
|
Phase 1 | |
| Completed |
NCT00513461 -
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
|
Phase 2 | |
| Active, not recruiting |
NCT02143401 -
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT02247401 -
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
|
Phase 3 | |
| Completed |
NCT02582632 -
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
|
Phase 3 | |
| Terminated |
NCT01532908 -
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
|
Phase 2 | |
| Recruiting |
NCT01754961 -
Effects of Vitamin D on Inflammation in Liver Disease
|
Phase 2 | |
| Terminated |
NCT01465516 -
Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir
|
N/A | |
| Completed |
NCT01265511 -
Study of SCY-635, Pegasys and Copegus in Hepatitis C
|
Phase 2 | |
| Completed |
NCT04042740 -
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
|
Phase 2 | |
| Not yet recruiting |
NCT05601518 -
Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.
|
||
| Terminated |
NCT02429583 -
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
|
Phase 4 | |
| Not yet recruiting |
NCT05506475 -
Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
|
||
| Terminated |
NCT01841502 -
Interaction Between Paroxetine and Telaprevir
|
Phase 2 | |
| Withdrawn |
NCT02112630 -
Boceprevir in End Stage Renal Disease (ESRD)
|
N/A | |
| Completed |
NCT02076100 -
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
|
Phase 1 | |
| Completed |
NCT01803308 -
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
|
Phase 1 | |
| Terminated |
NCT01560468 -
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection
|
Phase 1 |